Clinical Trials

Totus Clinical Trials

A Phase 1/​1b Study to Evaluate TOS-358 in Adults with Select Solid Tumors

Phase 1/1b

This phase 1/1b study is open and enrolling patients with hormone-receptor positive (HR+) breast, urothelial, endometrial or head & neck cancers that express PI3K-alpha mutations. Patients may be eligible for the study if they are 18 years or older, have good health status and life expectancy, no history of diabetes and no significant secondary cancers, heart conditions or other significant medical conditions (must meet all requirements for the study which will be assessed by the study doctor). TOS-358 is an oral medication taken once or twice daily. The purpose of the study is to evaluate the safety and tolerability of TOS-358 at different dose levels and to assess whether TOS-358 has any effect on tumors.

Preliminary results
from the study have been presented at a recent medical conference.

For more information and a list of participating clinical trial sites, clinicaltrials.gov Study NCT05683418 or email clinicaltrials@totusmedicines.com